Comparative Effect of Atorvastatin (80 mg) Versus Simvastatin (20 to 40 mg) in Preventing Hospitalizations for Heart Failure in Patients With Previous Myocardial Infarction

American Journal of Cardiology

Volumn 103, Issue 10, 2009, Pages 1381-1385

  Strandberg, Timo E ^a   Holme, Ingar ^c   Faergeman, Ole ^d   Kastelein, John J P ^e   Lindahl, Christina ^f   Larsen, Mogens Lytken ^d   Olsson, Anders G ^g   Pedersen, Terje R ^c   Tikkanen, Matti J ^b  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f Pfizer Sweden   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

FEMALE; HEART FAILURE; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 65449152570     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.377     Document Type: Article

References (12)

1. Pedersen T.R., Faergeman O., Kastelein J.J.P., Olsson A.G., Tikkanen M.J., Holme I., Lytken Larsen M., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. Design and baseline characteristics of the Incremental Decrease in End Points Through Aggressive Lipid Lowering study. Am J Cardiol 94 (2004) 720-724
2. Pedersen T.R., Faergeman O., Kastelein J.J.P., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., and Palmer G. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized, controlled trial. JAMA 294 (2005) 2437-2445
3. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
4. Khush K., Waters D., Bittner V., Deedwania P.C., Kastelein J.J.P., Lewis S.J., and Wenger N.K. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115 (2007) 576-583
5. Scirica B.M., Morrow D.A., Cannon C.P., Ray K.K., Sabatine M.S., Jarolim P., Shui A., McCabe C.H., and Braunwald E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47 (2006) 2326-2331
6. Martin J.H., and Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 113 (2007) 119-127
7. Horwich T.B., and MacLellan W.R. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother 8 (2007) 3061-3068
8. Sever P.S., Poulter N.R., Dahlof B., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristiansson A., McGinmnes G., et al. The Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm: extended observations 2 years after trial closure. Eur Heart J 29 (2008) 499-508
9. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G.F., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
10. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
11. Go A., Lee W., Yang J., Lo J., and Gurwitz J. Statin therapy and risks of death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
12. Rinfret S., Behlouli H., Eisenberg M.J., Humphries K., Tu J.V., and Pilote L. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. Am Heart J 155 (2008) 316-323